Evidence map›Paper›PMID 36040031›Full record

ArticlemBio2022

Olha Schneider, Martin Zehl, Reiko Ueoka, Christian Rückert, Tobias Buche, Yi Jiang, Qin-Yuan Li, Jörn Piel, Sergey B Zotchev

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Olha SchneiderDepartment of Pharmaceutical Sciences, Division of Pharmacognosy, University of Viennagrid.10420.37, Vienna, Austria.
Martin ZehlDepartment of Analytical Chemistry, Faculty of Chemistry, University of Viennagrid.10420.37, Vienna, Austria.
Reiko UeokaDepartment of Biology, Eidgenössische Technische Hochschule (ETH) Zurich, Zurich, Switzerland.
Christian RückertCenter for Biotechnology, Bielefeld Universitygrid.7491.b, Bielefeld, Germany.ORCID 0000-0002-9722-4435
Tobias BucheCenter for Biotechnology, Bielefeld Universitygrid.7491.b, Bielefeld, Germany.
Yi JiangYunnan Institute of Microbiology, Yunnan University, Kunming, People's Republic of China.ORCID 0000-0002-1847-252X
Qin-Yuan LiYunnan Institute of Microbiology, Yunnan University, Kunming, People's Republic of China.
Jörn PielDepartment of Biology, Eidgenössische Technische Hochschule (ETH) Zurich, Zurich, Switzerland.
Sergey B ZotchevDepartment of Pharmaceutical Sciences, Division of Pharmacognosy, University of Viennagrid.10420.37, Vienna, Austria.ORCID 0000-0002-9324-245X
University of Vienna · ATBielefeld University · DEBoard of the Swiss Federal Institutes of Technology · CHYunnan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The antibiotic desertomycin A and its previously undescribed inactive

Indexed as

StreptomycesAcetyltransferasesAmpicillinAnti-Bacterial AgentsEscherichia coliHydroxylysineKanamycinMacrolidesMultigene FamilyRecombinant ProteinsSecondary MetabolismSiderophoresAcetyltransferasesAmpicillinAnti-Bacterial Agentsdesertomycindesertomycin AHydroxylysineKanamycinMacrolidesRecombinant ProteinsSiderophoresantibiotic resistancedesertomycin analogueN-succinyltransferaseStreptomycessuccinyltransferase

Identifiers

PMID36040031
PMCPMC9600172
OpenAlexW4293568888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.